Chronic Obstructive Pulmonary Disease
Conditions
Keywords
cardiopulmonary exercise testing, cardiovascular comorbidities, cardiopulmonary interaction
Brief summary
In this study, cardiopulmonary exercise will be assessed to characterize the relevance of severity of COPD and coexisting cardiovascular comorbidities for exercise capacity.
Detailed description
In patients with chronic obstructive pulmonary disease (COPD) the interpretation of dyspnoea also needs to consider coexisting cardiovascular disease. Cardiopulmonary exercise testing (CPET) is used to characterize pulmonary and cardiac function and limitations during exercise. The investigators hypothesise that cardiopulmonary exercise is reduced in COPD patients with coexisting cardiovascular disease as well as in more symptomatic patients and in patients with frequent exacerbations. For this purpose, 100 patients with with stable COPD are characterized by clinical characteristics, laboratory tests, lung function, electrocardiography, echocardiography and cardiopulmonary exercise testing.
Interventions
OTHERMeasurement of lung function, electrocardiography, echocardiography and cardiopulmonary exercise testing
Measurement of lung function, electrocardiography, echocardiography and cardiopulmonary exercise testing
Sponsors
Klinik für Kardiologie, Pneumologie und Angiologie
Study design
Observational model
COHORT
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
40 Years to 40 Years
Inclusion criteria
* patients with stable chronic obstructive pulmonary disease, exacerbated or stable * 40-80 years * sinus rhythm * informed written consent
Exclusion criteria
* Inability to give written consent * acute myocardial infarction with ST-segment elevations in last 30 days * severe acute or chronic renal dysfunction * severe heart failure- * atrial fibrillation * severe valve disease * severe hypoxemia * long term oxygen therapy or non invasive ventilation
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Measurement of oxygen uptake during cardiopulmonary exercise testing (% predicted) | Baseline |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Measurement of FEV1 | Baseline | — |
| Measurement the capillary pO2 in mmHg and capillary pCO2 at baseline | Baseline | The blood gases pO2 and pCO2 are taken from the hyperaemic ear lobe to characterize the gas exchange during cardiopulmonary exercise which is a routine procedure |
| N-terminal pro brain natriuretic peptid (NTproBNP) in ng/L from peripheral venous blood at baseline | Baseline | NTproBNP is analysed from peripheral venous blood to characterize potential heart failure and its relation to exercise capacity of the study subjects |
| measurement of dyspnoea quantified by the COPD assessment test as well as the modified Medical Research Council Scale | Baseline | For the assessment of the symptoms of the study group and its relation to exercise capacity dyspnoea is assessed by accepted questionnaires typically used for COPD patients at baseline |
| Measurement of Breathing reserve during cardiopulmonary exercise testing | Baseline | BThe breathing reserve in % is assessed at the end of the cardiopulmonary exercise testing to characterize a ventilatory limitation of the exercise test. It is calculated as percent from the minute ventilation in relation to the maximum mandatory ventilation. The measurement is a routine measurement during cardiopulmonary exercise testing. |
| Measurement of Oxygen pulse during cardiopulmonary exercise testing | Baseline | — |
| Presence of cardiovascular comorbidities | Baseline | For the cardiopulmonary characterization clinical characteristics, lung function, blood gases, laboratory investigation, ECG and echocardiography were used in addition to cardiopulmonary exercise testing. |
| Measurement of Maximum wattage during cardiopulmonary exercise testing | Baseline | — |
Countries
Germany
Contacts
Primary ContactStefanie Keymel, MD
Backup ContactRabea Wagstaff, M.A.
Outcome results
None listed